OpenExamsFREE PRACTICE — ANY EXAM

Nebraska Pharmacist — Requirements & Free Practice

US-NE · License preparation

850 free questions · Answer explanations · No signup required

Choose what to practice

Start with an exam below. Your examination requirements depend on your application pathway. View licensing requirements

Combined practice

Choose an exam or combined practice to begin.

Licenses, application pathways and examination requirements

Each license and applicant pathway has its own requirements and exemptions. Choosing practice questions does not determine your eligibility.

Pharmacist License

License to practice pharmacy in Nebraska issued under the Pharmacy Practice Act (Neb. Rev. Stat. § 38-2851) and 172 NAC 128.

Licensing authority: Nebraska Department of Health and Human Services, Division of Public Health, Licensure Unit (with the recommendation of the Nebraska Board of Pharmacy) · Application information

Licensure by examination (NAPLEX taken for Nebraska)

All of the following:

Application Form
The DHHS application form, Section E, still describes this pathway as "taking the NAPLEX for Nebraska and taking the Nebraska MPJE" without mentioning the UMPJE; the Board page names "NAPLEX and Nebraska MPJE or uMPJE".
Current Competency
If NAPLEX was not passed within the last three years, proof of one current-competency alternative: one year of active practice in another jurisdiction within the last three years, Board of Pharmacy Specialties certification within seven years, licensure in another jurisdiction, or Board-approved continuing competency (Neb. Rev. Stat. § 38-2851(2)(c); 172 NAC 128-003.01(C)).
Education
Proof of graduation from an accredited pharmacy program, sent directly by the program (Neb. Rev. Stat. § 38-2851(1); 172 NAC 128-003.01(A)).
General
Applicant must be at least 19 years old and show citizenship or lawful presence (Neb. Rev. Stat. § 38-129, per the application form).
Jurisprudence Exam Sources
172 NAC 128-003.01(B)(ii) (regulation, effective 2020-11-03) names only the "Multistate Pharmacy Jurisprudence Examination (MPJE) for Nebraska"; the Board page accepts "Nebraska MPJE or uMPJE" and NABP lists Nebraska as a UMPJE jurisdiction from June 1, 2026 with MPJE retirement on May 31, 2028. The rule predates the UMPJE and is silent on it, so both examinations are listed as alternatives.
Passing Scores
A score of 75 or above on NAPLEX and on the MPJE for Nebraska (172 NAC 128-003.01(B)); NABP determines eligibility to take the examinations.
Prior Evidence
172 NAC 128-003.01(B)(i) also accepts a passing score on the predecessor of NAPLEX given by NABP; that examination is no longer offered and counts only as prior evidence.
Licensure of foreign pharmacy graduates

All of the following:

Current Competency
If NAPLEX was not passed within the last three years, proof of one current-competency alternative: one year of active practice in another jurisdiction within the last three years, Board of Pharmacy Specialties certification within seven years, licensure in another jurisdiction, or Board-approved continuing competency (Neb. Rev. Stat. § 38-2851(2)(c); 172 NAC 128-003.01(C)).
Foreign Graduate
Graduate of a pharmacy program outside the United States that is not accredited, with evidence of graduation satisfactory to the department on the Board's recommendation (Neb. Rev. Stat. § 38-2851(1)).
Fpgec Certification
Foreign Pharmacy Graduate Examination Committee (FPGEC) Certification given by NABP (172 NAC 128-003.01(A)); per NABP a passing FPGEE score of 75 or higher is needed to complete the FPGEC Certification application. Any other FPGEC Certification components are set by NABP.
General
Applicant must be at least 19 years old and show citizenship or lawful presence (Neb. Rev. Stat. § 38-129, per the application form).
Jurisprudence Exam Sources
172 NAC 128-003.01(B)(ii) (regulation, effective 2020-11-03) names only the "Multistate Pharmacy Jurisprudence Examination (MPJE) for Nebraska"; the Board page accepts "Nebraska MPJE or uMPJE" and NABP lists Nebraska as a UMPJE jurisdiction from June 1, 2026 with MPJE retirement on May 31, 2028. The rule predates the UMPJE and is silent on it, so both examinations are listed as alternatives.
Passing Scores
A score of 75 or above on NAPLEX and on the MPJE for Nebraska (172 NAC 128-003.01(B)); NABP determines eligibility to take the examinations.
Prior Evidence
172 NAC 128-003.01(B)(i) also accepts a passing score on the predecessor of NAPLEX given by NABP; that examination is no longer offered and counts only as prior evidence.
Translated Transcript
A translated copy of the pharmacy school transcript sent directly to the Department (application form, Section D).
Licensure by reciprocity (NABP licensure transfer)

All of the following:

Current Competency
If NAPLEX was not passed within the last three years, proof of one current-competency alternative: one year of active practice in another jurisdiction within the last three years, Board of Pharmacy Specialties certification within seven years, licensure in another jurisdiction, or Board-approved continuing competency (Neb. Rev. Stat. § 38-2851(2)(c); 172 NAC 128-003.01(C)).
Education
Proof of graduation from an accredited pharmacy program, sent directly by the program (Neb. Rev. Stat. § 38-2851(1); 172 NAC 128-003.01(A)).
General
Applicant must be at least 19 years old and show citizenship or lawful presence (Neb. Rev. Stat. § 38-129, per the application form).
Jurisprudence Exam Sources
172 NAC 128-003.01(B)(ii) (regulation, effective 2020-11-03) names only the "Multistate Pharmacy Jurisprudence Examination (MPJE) for Nebraska"; the Board page accepts "Nebraska MPJE or uMPJE" and NABP lists Nebraska as a UMPJE jurisdiction from June 1, 2026 with MPJE retirement on May 31, 2028. The rule predates the UMPJE and is silent on it, so both examinations are listed as alternatives.
Nabp Transfer Rule
NABP's UMPJE Participating States table lists Nebraska with "UMPJE Required for Licensure Transfer: Yes".
Naplex Previously Passed
The Board page states that reciprocity "requires the applicant to successfully complete the Nebraska MPJE or uMPJE" and does not name NAPLEX; Neb. Rev. Stat. § 38-2851(2)(a) and 172 NAC 128-003.01(B)(i) require every pharmacist license applicant to have passed NAPLEX, so the NAPLEX passed for the original license is required evidence.
Other License
Licensed as a pharmacist in another state, territory, or the District of Columbia in which, under like conditions, licensure is granted in Nebraska (Neb. Rev. Stat. § 38-2851(2)(c)(iv)); Licensure Transfer Document requested from NABP (application form, Section E).
Passing Scores
A score of 75 or above on NAPLEX and on the MPJE for Nebraska (172 NAC 128-003.01(B)); NABP determines eligibility to take the examinations.
Prior Evidence
172 NAC 128-003.01(B)(i) also accepts a passing score on the predecessor of NAPLEX given by NABP; that examination is no longer offered and counts only as prior evidence.
Reinstatement of an expired or inactive pharmacist license
No examination is required for this applicant pathway.
Continuing Competency
30 hours of acceptable continuing education in the 24 months before the reinstatement application, unless waived (reinstatement application, Section C).
Fees
Renewal and reinstatement fees (reinstatement application).
Prior License
Previously licensed as a pharmacist in Nebraska with a license that expired or was placed on inactive status (172 NAC 10-007.01(A)).

Official no-examination sources

Effective from 2026-09-22.

Renewal of a pharmacist license
No examination is required for this applicant pathway.
Continuing Competency
30 hours of continuing education from an approved provider in the 24 months before renewal, or an approved specialty or diabetes educator certification (172 NAC 128-005).
Expiration
Pharmacist licenses expire on January 1 of each even-numbered year (172 NAC 128-004.01).

Official no-examination sources

Effective from 2026-09-22.

Licensure by NAPLEX score transfer

All of the following:

Current Competency
If NAPLEX was not passed within the last three years, proof of one current-competency alternative: one year of active practice in another jurisdiction within the last three years, Board of Pharmacy Specialties certification within seven years, licensure in another jurisdiction, or Board-approved continuing competency (Neb. Rev. Stat. § 38-2851(2)(c); 172 NAC 128-003.01(C)).
Education
Proof of graduation from an accredited pharmacy program, sent directly by the program (Neb. Rev. Stat. § 38-2851(1); 172 NAC 128-003.01(A)).
General
Applicant must be at least 19 years old and show citizenship or lawful presence (Neb. Rev. Stat. § 38-129, per the application form).
Jurisprudence Exam Sources
172 NAC 128-003.01(B)(ii) (regulation, effective 2020-11-03) names only the "Multistate Pharmacy Jurisprudence Examination (MPJE) for Nebraska"; the Board page accepts "Nebraska MPJE or uMPJE" and NABP lists Nebraska as a UMPJE jurisdiction from June 1, 2026 with MPJE retirement on May 31, 2028. The rule predates the UMPJE and is silent on it, so both examinations are listed as alternatives.
Naplex Score Transfer
NAPLEX taken for another jurisdiction, with a NAPLEX score transfer report requested from NABP to Nebraska (Board page "Score Transfer").
Passing Scores
A score of 75 or above on NAPLEX and on the MPJE for Nebraska (172 NAC 128-003.01(B)); NABP determines eligibility to take the examinations.
Prior Evidence
172 NAC 128-003.01(B)(i) also accepts a passing score on the predecessor of NAPLEX given by NABP; that examination is no longer offered and counts only as prior evidence.
Credential by reciprocity under the Uniform Credentialing Act (Neb. Rev. Stat. § 38 129.02)

All of the following:

  • Multistate Pharmacy Jurisprudence Examination (MPJE) for Nebraska (practice unavailable)
Discipline
No revocation, other disciplinary action, voluntary surrender under investigation, pending complaint, or disqualifying criminal history (§ 38-129.02(3)(f)-(g), (5)).
Limits
A credential issued under this section is not valid for an interstate compact or for reciprocity provisions of any practice act (§ 38-129.02(2)).
Nebraska Law Exam
A passing score on a credentialing examination specific to the laws of Nebraska "if required by the appropriate board" (§ 38-129.02(3)(h)). The Board of Pharmacy's rule names the MPJE for Nebraska as the pharmacist jurisprudence examination (172 NAC 128-003.01(B)(ii)); no obtained Board rule or page states whether it requires that examination of § 38-129.02 applicants.
Other Credential
A pharmacist credential that is current and valid in another state, territory, or the District of Columbia and has been valid for at least one year, with documentation of its level, educational requirements, and any work experience and clinical supervision requirements (Neb. Rev. Stat. § 38-129.02(2)-(3)).
Other Jurisdiction Exam
Passage of the examination the other jurisdiction required for that credential (Neb. Rev. Stat. § 38-129.02(3)(e)); the statute does not name the examination.
Residency
Establish Nebraska residency within 180 days after issuance, or the credential is automatically revoked (§ 38-129.02(4)).

Multistate Pharmacy Jurisprudence Examination (MPJE) for Nebraska

Provider
National Association of Boards of Pharmacy
Format
Computer-based adaptive examination of selected-response questions
Exam questions
120 questions (100 operational scored items and 20 pretest unscored items)
Time limit
2.5 hours
Examination outline
  • Area 1 — Licensure/Personnel (22%)
    • 1.1 – Responsibilities of the pharmacist and non-pharmacist personnel
    • Qualifications, scope of duties, limitations, and restrictions of duties, or conditions to practice for pharmacists-in-charge (or equivalent) and pharmacists
    • Qualifications, scope of duties, limitations, and restrictions of duties, or conditions to practice for non-pharmacist personnel
    • 1.2 – Licensures, registrations, and certifications for pharmacists or non-pharmacist personnel
    • Qualifications, examinations, internships, maintaining pharmacist competency, and renewals of licensures, registrations, or certifications
    • Classifications and processes of disciplinary actions
    • Reporting to and participating in programs addressing the inability to practice with reasonable skill and safety
  • Area 2 — Pharmacist Practice (33%)
    • 2.1 – Requirements for issuing prescriptions/drug orders
    • Requirements for drug uses, limitations, or restrictions
    • Scope of authority, scope of practice, limitations or restrictions of practice, and valid registration of practitioners who are authorized to prescribe, dispense, or administer drugs
    • Requirements for issuing non-controlled prescriptions/drug orders
    • Requirements for issuing controlled prescriptions/drug orders
    • Authority limitations of practitioners’ ability to authorize refills
    • 2.2 – Conditions under which the pharmacist or non-pharmacist personnel participates in the administration of drugs in the management of patients’ therapy
    • 2.3 – Requirements regarding counseling
    • Counseling or offering to counsel
    • Documenting counseling or documenting offering to counsel
    • 2.4 – Returning or reusing drugs
    • 2.5 – Regulations and agencies regarding pharmacy practice
    • Requirements for promoting quality and safety of public health
    • Protecting patient and health record confidentiality
  • Area 3 — Dispensing Requirements (24%)
    • 3.1 – Responsibilities for determining whether prescriptions/drug orders are issued for a legitimate medical purpose, and within all applicable restrictions
    • 3.2 – Transferring prescription/drug order information between pharmacies by authorized personnel
    • 3.3 – Prospective drug utilization reviews
    • Requirements for reporting to PMP and accessing PMP data
    • 3.4 – Exceptions to dispensing or refilling prescriptions/drug orders
    • 3.5 – Labeling of dispensed drugs
    • 3.6 – Packaging of dispensed drugs
    • 3.7 – Drug product conditions prohibiting dispensing
    • 3.8 – Requirements for the distribution and/or dispensing of non-prescription pharmaceutical products, including controlled substances and hazardous drugs
    • Dispensing or administration
    • Labeling of non-prescription drugs and devices
    • Packaging and repackaging of non-prescription drugs and behind-the-counter products
    • Dispensing-restricted, non-prescription drugs
  • Area 4 — Pharmacy Operations (21%)
    • 4.1 – Ordering, acquisition, and distribution of drugs, including maintenance and content of such records
    • Ordering and acquisition, including the maintenance and content of such records
    • Distribution, including the maintenance and content of such records
    • 4.2 – Recordkeeping in compliance with legal requirements, including content, inventory, maintenance, storage, handling, and reporting
    • Non-dispensing requirements for operations of pharmacies or practice settings
    • Possession, storage, and handling of non-hazardous drugs
    • Training, possession, handling, storage, and disposal of hazardous drugs
    • Allowing non-pharmacist personnel access to drugs
    • Requirements for conducting controlled substance inventories
    • 4.3 – Delivery of drugs
    • 4.4 – Conditions for permitted or mandated product selection
    • 4.5 – Compounding sterile, nonsterile, hazardous, and non-hazardous preparations
    • 4.6 – Centralized prescription processing or central-fill pharmacy dispensing
    • 4.7 – Requirements for the registration, licensure, certification, or permitting of a practice setting or business entity
    • Requirements for registration, license, certification, or permitting of a practice setting
    • Requirements for the renewal or reinstatement of a license, registration, certificate, or permit of a practice setting
    • Requirements for an inspection of a licensed, registered, certified, or permitted practice setting
    • Classifications and processes of disciplinary actions that may be taken against a registered, licensed, certified, or permitted practice setting
Examination sources

Foreign Pharmacy Graduate Equivalency Examination

Provider
National Association of Boards of Pharmacy
Format
Computerized fixed form
Exam questions
200 questions
Time limit
4.5 hours examination time; 5.5 hours total seat time
Passing score
Scaled score of 75
Examination outline
  • Foundational Biomedical Sciences (12%)
    • Anatomy and physiology
    • Biochemistry
    • Medical microbiology
    • Immunology
    • Pathophysiological bases of diseases
  • Pharmaceutical Sciences (31%)
    • Pharmaceutical calculations (eg, dose adjustments, delivery, ionization, ionic strength, isotonicity, ratio/percentage strength, osmolarity)
    • Medicinal chemistry
    • Medicinal chemistry: Physicochemical properties of drugs in relation to drug absorption, distribution, metabolism, and excretion (ADME)
    • Medicinal chemistry: Pathways of drug metabolism
    • Medicinal chemistry: Chemical bases for drug action, including bioorganic chemistry, structure-activity relationships, and fundamental pharmacophores related to drug-receptor interactions
    • Medicinal chemistry: Applicability to making drug therapy decisions
    • Pharmacology and toxicology
    • Pharmacology and toxicology: Pharmacodynamics, including drug-receptor interactions, agonists, antagonists, inverse agonists, and dose-response curves
    • Pharmacology and toxicology: Mechanisms of action of drugs, including biologics
    • Pharmacology and toxicology: Adverse effects and side effects of drugs
    • Pharmacology and toxicology: Mechanisms of drug interactions, including drug-drug, drug-disease, drug-food, drug-allergy, and drug-laboratory interactions
    • Pharmacology and toxicology: Mechanisms of acute and chronic toxic effects of xenobiotics, including drug and chemical overdose or exposure and antidotes
    • Pharmaceutics and biopharmaceutics
    • Pharmaceutics and biopharmaceutics: Dosage form development and drug delivery systems such as immediate release, sustained release, and controlled release
    • Pharmaceutics and biopharmaceutics: Disintegration and dissolution of solid oral dosage forms
    • Pharmaceutics and biopharmaceutics: Physicochemical properties of drugs, excipients, solutions, and dosage forms
    • Pharmaceutics and biopharmaceutics: Physical stability, chemical stability, and shelf-lives, including zero-, first-, second-, and pseudo-order reactions
    • Pharmaceutics and biopharmaceutics: Interactions between drug formulation and biological effects
    • Pharmaceutics and biopharmaceutics: Drug product manufacturing, including methods, processing, and quality assurance
    • Pharmacokinetics
    • Pharmacokinetics: Determining rates of absorption, distribution, metabolism, and excretion (ADME) of drugs
    • Pharmacokinetics: Factors affecting rates of ADME, including age, sex, genetics, diet, disease, and drug interactions
    • Pharmacokinetics: Biological half-lives of drugs and related dosing
    • Pharmacokinetics: Compartment models (one-, two-, and non-)
    • Pharmacokinetics: Linear and nonlinear pharmacokinetics
    • Pharmacokinetics: Principles of bioavailability, bioequivalence, and biosimilars
    • Pharmacogenomics (eg, population-based genetic influences on drug metabolism and efficacy, genetic testing, tumor genotyping, pharmacogenetic screening)
    • Extemporaneous compounding (eg, United States Pharmacopeia (USP) standards including Chapters <795>, <797>, and <800>; dosage form preparation calculations; techniques used to prepare and dispense sterile and nonsterile preparations)
  • Social, Behavioral, and Administrative Sciences (20%)
    • Pharmacy law and ethics
    • Pharmacy law and ethics: Laws and regulations governing pharmacy
    • Pharmacy law and ethics: Regulatory, oversight, and professional organizations
    • Pharmacy law and ethics: Principles and application of biomedical ethics
    • Health care systems
    • Health care systems: Organization, regulation, and financing of health care delivery in the United States
    • Health care systems: Factors that influence delivery and use of health care (eg, social, political, economic, and technological)
    • Pharmacoeconomics (eg, analysis, interpretation, application, humanistic outcomes)
    • Population-based care, pharmacoepidemiology, and public health
    • Population-based care, pharmacoepidemiology, and public health: Data sources and analytic tools
    • Population-based care, pharmacoepidemiology, and public health: Application of epidemiological study design
    • Population-based care, pharmacoepidemiology, and public health: Health promotion, disease prevention, and infection control
    • Population-based care, pharmacoepidemiology, and public health: Continuous quality improvement
    • Population-based care, pharmacoepidemiology, and public health: Social determinants and drivers of health
    • Practice management
    • Practice management: Financial management and budgeting
    • Practice management: Personnel management
    • Practice management: Business and strategic planning
    • Practice management: Risk management
    • Practice management: Procurement and inventory control
    • Professional communication
    • Professional communication: Verbal, nonverbal, written, and technology-based communication with patients, caregivers, providers, and stakeholders
    • Professional communication: Health literacy
    • Biostatistics and research methods (eg, study design, statistical tests, data collection instruments, research ethics)
    • Social and behavioral aspects of practice
    • Social and behavioral aspects of practice: Patient behavior including health-, illness-, and sick-role
    • Social and behavioral aspects of practice: Principles of behavior modification
    • Social and behavioral aspects of practice: Patient adherence
    • Social and behavioral aspects of practice: Cultural awareness
  • Pharmacy Practice and Clinical Sciences (37%)
    • Clinical pathophysiology as it applies to treatment of disease processes
    • Data collection (eg, patient history, physical assessments, laboratory values, point-of-care testing)
    • Data assessment (eg, clinical calculations, interpretation of data, diagnosing)
    • Patient-care decision making, therapy recommendations, and education (eg, plan, implement, monitor, follow-up)
    • Patient safety (eg, drug interactions, toxicity, drug-induced disease, drug use disorders)
    • Disease prevention (eg, screenings, immunization, non-pharmacological therapies, lifestyle modifications)
    • Personalized medicine (eg, pharmacokinetics, pharmacogenetics)
    • Evidence-based practice
    • Evidence-based practice: Practice guidelines
    • Evidence-based practice: Drug information and evaluation
    • Evidence-based practice: Information source reliability
    • Evidence-based practice: Clinical trial evaluation
    • Self-care, including using natural products
Examination sources

North American Pharmacist Licensure Examination

Provider
National Association of Boards of Pharmacy
Format
Computerized fixed form
Exam questions
225 questions
Time limit
6 hours
Passing score
Pass or Fail
Examination outline
  • Foundational Knowledge for Pharmacy Practice (25%)
    • Pharmaceutical science principles and concepts
    • Pharmaceutical science principles and concepts: Pharmacology
    • Pharmaceutical science principles and concepts: Pharmacokinetics, pharmacodynamics, or pharmacogenomics
    • Pharmaceutical science principles and concepts: Pharmaceutics
    • Pharmaceutical compounding
    • Pharmaceutical compounding: Nonsterile preparations
    • Pharmaceutical compounding: Sterile preparations
    • Pharmaceutical calculations
    • Pharmaceutical calculations: Patient parameters or laboratory measures
    • Pharmaceutical calculations: Quantities of drugs to be dispensed or administered
    • Pharmaceutical calculations: Rates of administration
    • Pharmaceutical calculations: Dose conversions
    • Pharmaceutical calculations: Drug concentrations, ratio strengths, osmolarity, or osmolality
    • Pharmaceutical calculations: Quantities of drugs or ingredients to be compounded
    • Pharmaceutical calculations: Nutritional needs and the content of nutrient sources
    • Pharmaceutical calculations: Biostatistical, epidemiological, or pharmacoeconomic measures
    • Pharmaceutical calculations: Pharmacokinetic parameters
    • Drug development processes (eg, clinical trial phases, emergency use authorizations)
    • Research design principles and biostatistics (eg, blinding, randomization, biases, statistical tests and outcomes, ethics)
    • Retrieval, assessment, and interpretation of primary, secondary, and tertiary resources
  • Medication Use Process (Prescribing, Transcribing and Documenting, Dispensing, Administering, and Monitoring) (25%)
    • Prescriptions and medication order interpretation
    • Prescriptions and medication order interpretation: Drug names and therapeutic classes
    • Prescriptions and medication order interpretation: Indications, usage, and dosing regimens
    • Prescriptions and medication order interpretation: Available dosage forms
    • Prescriptions and medication order interpretation: Prescription regulations (eg, boxed warnings, risk evaluation and mitigation strategies)
    • Prescriptions and medication order interpretation: Safety and effectiveness (eg, laboratory parameters, vital signs)
    • Therapeutic substitutions (eg, formulary restrictions, therapeutic alternatives, shortages, biosimilars)
    • Immunization services and documentation
    • Immunization services and documentation: Indications and scheduling
    • Immunization services and documentation: Contraindications and precautions
    • Immunization services and documentation: Storage and handling
    • Immunization services and documentation: Administration (eg, techniques, preparation, routes)
    • Immunization services and documentation: Adverse reactions
    • Medication handling, storage, stability, and disposal (eg, hazardous and nonhazardous drugs, controlled substances, parenteral medications, sharps handling, temperature control)
  • Person-Centered Assessment and Treatment Planning (40%)
    • Medication history, allergy history, and reconciliation
    • Health histories, screenings, and assessments
    • Patient health conditions, including special populations and medication-related factors
    • Patient health conditions, including special populations and medication-related factors: Signs, symptoms, and findings of medical conditions, etiology of diseases, or pathophysiology
    • Patient health conditions, including special populations and medication-related factors: Appropriateness of therapy (eg, medications, immunizations, non-drug therapy, dosing, contraindications, warnings, evidence-based decision making)
    • Patient health conditions, including special populations and medication-related factors: Interactions (eg, drug-drug, drug-condition, drug-food, drug-allergy, drug-laboratory)
    • Patient health conditions, including special populations and medication-related factors: Errors and omissions (eg, dosing, duplication, additional therapy needed, unnecessary therapy)
    • Patient health conditions, including special populations and medication-related factors: Adverse drug reactions
    • Patient health conditions, including special populations and medication-related factors: Toxicologic exposures and overdoses
    • Patient health conditions, including special populations and medication-related factors: Adherence
    • Therapeutic monitoring, plan development, evaluation, and modifications
    • Therapeutic monitoring, plan development, evaluation, and modifications: Therapeutic goals, clinical endpoints, and follow-up
    • Therapeutic monitoring, plan development, evaluation, and modifications: Safety
    • Therapeutic monitoring, plan development, evaluation, and modifications: Effectiveness
    • Patient education
    • Patient education: Lifestyle modifications and health maintenance
    • Patient education: Medication use, storage, and disposal
    • Patient education: Disease state management
    • Over-the-counter medications and dietary supplements
    • Devices to administer medications and self-monitoring tests
  • Professional Practice (5%)
    • Adverse drug event reporting and medication error reporting (eg, MedWatch, VAERS)
    • Public health initiatives and risk-prevention programs (eg, tobacco and nicotine cessation, antimicrobial stewardship, health screenings, opioid stewardship)
    • Social determinants and drivers of health
    • Ethical considerations (eg, informed consent, ethical principles, professional conduct and responsibility, patient confidentiality)
  • Pharmacy Management and Leadership (5%)
    • Pharmacy operations (eg, operational planning, risk management, regulations and regulatory bodies, technology applications and informatics, error-prevention strategies, medication safety)
    • Inventory and supply management (eg, drug recalls, drug shortages)
    • Quality improvement activities (eg, medication use evaluation, root-cause analysis, continuous quality improvement)
    • Mentorship and preceptorship (eg, providing and receiving feedback, delegation of work activities, preceptor roles)
Examination sources

Uniform MPJE

Provider
National Association of Boards of Pharmacy
Format
Computer-based adaptive selected-response examination
Exam questions
120 questions
Time limit
2.5 hours
Passing score
Pass or Fail
Examination outline
  • Pharmacy and Pharmacist Practice (30%)
    • Practice of pharmacy definition (eg, scope of authority, scope of practice, collaborative practice agreements and other delegative authorities, limitations or restrictions on practice)
    • Non-pharmacist personnel (eg, supervision, scope, licensure, counseling)
    • Adulterated or misbranded medications (eg, medication recalls, expiration dates, counterfeit medications, emergency use authorizations, importation, Drug Supply Chain Security Act (DSCSA))
    • Federal regulatory standards (eg, National Institute for Occupational Safety and Health (NIOSH), Occupational Safety and Health Administration (OSHA), essential copies of commercial products, patient-specific prescription requirements, anticipatory compounding)
    • United States Pharmacopeia (USP) standards on compounding and hazardous materials (eg, beyond-use dating, competency training, environmental testing, record keeping)
    • Security of patient health information
  • Medication Use Process (Prescribing, Transcribing and Documenting, Dispensing, Administering, and Monitoring) (30%)
    • Requirements for issuing prescriptions and medication orders, including controlled substances
    • Requirements for issuing prescriptions and medication orders, including controlled substances: Validity of a prescription (eg, authority, content, corresponding responsibility)
    • Requirements for issuing prescriptions and medication orders, including controlled substances: Changes to a prescription
    • Requirements for issuing prescriptions and medication orders, including controlled substances: Emergency prescriptions and emergency refills
    • Dispensing medications, including controlled substances
    • Dispensing medications, including controlled substances: Pharmacy and manufacturer labeling, including over-the-counter medications and patient education
    • Dispensing medications, including controlled substances: Drug utilization review
    • Dispensing medications, including controlled substances: Fills, refills, and partial fills
    • Dispensing medications, including controlled substances: Packaging and repackaging
    • Dispensing medications, including controlled substances: Counseling
    • Dispensing medications, including controlled substances: Transfers
    • Dispensing medications, including controlled substances: Prescription drug monitoring program (PDMP) requirements
    • Dispensing medications, including controlled substances: Recalls, returns, and reuse
    • Dispensing medications, including controlled substances: Drug product selection (eg, substitutions, interchangeability)
    • Administration of medications, including adverse event reporting
  • Regulatory Authority and Legal Obligations (20%)
    • Role of regulatory authorities, including authority, inspections, and discipline
    • Role of regulatory authorities, including authority, inspections, and discipline: Federal (eg, Food and Drug Administration (FDA), Drug Enforcement Administration (DEA), US Department of Health and Human Services (HHS))
    • Role of regulatory authorities, including authority, inspections, and discipline: State (eg, board of pharmacy, department of health)
    • Controlled substances
    • Controlled substances: Inventory
    • Controlled substances: Record keeping
    • Controlled substances: Order forms and ordering
    • Controlled substances: DEA registration and power of attorney
    • Controlled substances: Theft and loss
    • Controlled substances: Disposal
    • Liability and malpractice
  • Pharmacy Operations (20%)
    • Licensures, registrations, and certifications
    • Pharmacy technology, including record keeping and automation (eg, e-prescribing, faxing, shared services)
    • Access, storage, handling, and security
Examination sources